story of the week
Phase III Data Show Bayer’s Stivarga (Regorafenib) Improved Overall Survival in Previously Treated Patients With Unresectable Liver Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: